Riskpilot← Back to searchSign inGet full accessOncoSpear ApS
APSActiveCVR 42093734Lucernevej 2Manufacture of pharmaceutical preparations · NACE 2120Est. 20218 employees
Revenue 2024
DKK -4,7M
-14% vs 2023
EBITDA margin
172.9%
+1% vs 2023
Equity ratio
42.8%
Financial strength
Net profit 2024
DKK -6,5M
+3% vs 2023
| Revenue | DKK -4,7M | -14% |
| EBITDA | DKK -8M | +1% |
| Net profit | DKK -6,5M | +3% |
| Total assets | DKK 3,3M | -65% |
| Equity | DKK 1,4M | -82% |
| Employees | 8 | — |
Legal name
OncoSpear ApS
CVR number
42093734
Legal form
Anpartsselskab
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
1. februar 2021
Share capital
DKK 108.889
Employees
8 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af den samlede direktion
Company purpose
Selskabets formål er at udvikle, markedsføre, licensere og sælge lægemidler, herunder at udvikle en forskningsplatform, der vil blive brugt til at identificere receptorer, der kan binde til lægemiddelkandidater, samt dermed beslægtede aktiviteter.
Address
Lucernevej 2
Phone
+4521733311
Email
j.graversen@spicatx.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue | -26 | -640 | -5.396 | -4.652 |
| Staff expenses | -0 | -588 | -2.751 | -3.389 |
| EBITDA | -26 | -1.228 | -8.147 | -8.041 |
| Depreciation & amort. | -0 | -0 | -0 | -0 |
| EBIT | -26 | -1.228 | -8.147 | -8.041 |
| Net financials | -0 | -0 | -0 | -4 |
| Profit before tax | -26 | -1.228 | -8.147 | -8.045 |
| Tax | -0 | -138 | -1.452 | -1.584 |
| Net profit | -26 | -1.090 | -6.694 | -6.461 |
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Total assets | 33 | 7.510 | 9.253 | 3.251 |
| Equity | 24 | 7.112 | 7.853 | 1.392 |
| Long-term debt | 0 | 0 | 0 | 676 |
| Short-term debt | 10 | 397 | 1.400 | 1.183 |
| Total debt | 10 | 397 | 1.400 | 1.859 |
EBITDA margin
-804136000.0%
This company
15.8%
Market median
-5089468454% vs market
20212024
Equity ratio
42.8%
This company
38.2%
Market median
+12% vs market
20212024
Return on equity
-464.3%
This company
18.4%
Market median
-2623% vs market
20212024
Net profit margin
-646113900.0%
This company
8.1%
Market median
-7976714915% vs market
20212024
Asset turnover
-1.43×
This company
1.12×
Market median
-228% vs market
20212024
Debt / equity
1.34×
This company
0.62×
Market median
-116% vs market
20212024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-02-01 – 2021-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
TL Founder | Founder | 2021 | — | — |
GG Management | Management | 2024 | — | — |
NJ Management | Management | 2021 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2021 | — | — | |
| Chairman | 2021 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2021 | — | — | |
| Chairman | 2023 | — | — | |
| Board of Directors | 2021 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100.0% | 100.0% | 2024 | |
| Individual | 50.0% | 50.0% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of OncoSpear ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Toby Lawrence | Founder | 0 companies |
| Geert Gilbert Tackaert | Management | 0 companies |
| Niels Jonas Heilskov Graversen | Management | 0 companies |
| Anders Etzerodt | Board of Directors | 0 companies |
| Søren Kragh Moestrup | Chairman | 0 companies |
| Alexander Bharmal Demoulin | Board of Directors | 0 companies |
| Jens Kristian Damsgaard | Board of Directors | 0 companies |
| Debora Catharina Dumont | Chairman | 0 companies |
| Holger Jon Møller | Board of Directors | 0 companies |